It is made available under a CC-BY-NC-ND 4.0 International license .

Psilocybin alters brain activity related to sensory and cognitive processing in a time-dependent manner

3

4

Marek Nikolic^{1,2}, Pedro Mediano^{3,4}, Tom Froese⁵, David Reydellet⁶ Tomas Palenicek^{1,2,*}

¹3rd Medical Faculty, Charles University, Prague

²Psychedelic Research Centre, National Institute of Mental Health, Czechia

³Department of Computing, Imperial College London

⁴Division of Psychology and Language Sciences, University College London

⁵Embodied Cognitive Science Unit, Okinawa Institute of Science and Technology

⁶Division of Psychiatry, Department of Brain Sciences, Centre for Psychedelic Research, Imperial College London

*Correspondence: tomas.palenicek@nudz.cz

September 2024

5 Keywords: Keywords: EEG, Signal Complexity, Psychedelics, Power Spectral Density

Abstract: Psilocybin is a classic psychedelic and a novel treatment for mood disorders. 6 Psilocybin induces dose-dependent transient (4-6 hours) usually pleasant changes in percep-7 tion, cognition, and emotion by non-selectively agonizing the 5-HT_{2A} receptors and negatively 8 regulating serotonin reuptake, and long-term positive antidepressant effect on mood and well-9 being. Long-term effects are ascribed to the psychological quality of the acute experience, 10 increase in synaptodensity and temporary (1-week) down-regulation of 5-HT_{2A} receptors. 11 Electroencephalography, a non-invasive neuroimaging tool, can track the acute effects of 12 psilocybin; these include the suppression of alpha activity, decreased global connectivity, and 13 increased brain entropy (i.e. brain signal diversity) in eyes-closed resting-state. However, 14 few studies investigated how these modalities are affected together through the psychedelic 15 experience. The current research aimed to evaluate the psilocybin intoxication temporal EEG 16

It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION 1

2

profile. 20 healthy individuals (10 women) underwent oral administration of psilocybin (0.26 17 mg/kg) as part of a placebo-controlled cross-over study, resting-state 5-minute eyes closed 18 EEG was obtained at baseline and 1, 1.5, 3, 6, and 24 hours after psilocybin administration. 19 Absolute power, relative power spectral density (PSD), power envelope global functional 20 connectivity (GFC), Lempel-Ziv complexity (LZ), and a Complexity via State-Space Entropy 21 Rate (CSER) were obtained together with measures of subjective intensity of experience. 22 Absolute power decreased in alpha and beta band, but increased in delta and gamma fre-23 quencies. 24h later was observed a broadband decrease. The PSD showed a decrease in 24 alpha occipitally between 1 and 3 hours and a decrease in beta frontally at 3 hours, but 25 power spectra distribution stayed the same 24h later. The GFC showed decrease acutely 26 at 1, 1.5, and 3 hours in the alpha band. LZ and showed an increase at 1 and 1.5 hours. 27 Decomposition of CSER into functional bands shows a decrease in alpha band but increase 28 over higher frequencies. Further, complexity over a source space showed opposing changes 29 in the Default Mode Network (DMN) and visual network between conditions, suggesting a 30 relationship between signal complexity, stimulus integration, and perception of self. In an 31 exploratory attempt, we found that a change in gamma GFC in DMN correlates with oceanic 32 boundlessness. Psychological effects of psilocybin may be wrapped in personal interpreta-33 tions and history unrelated to underlying neurobiological changes, but changes to perception 34 of self may be bound to perceived loss of boundary based on whole brain synchrony with the 35 DMN in higher frequency bands. 36

Introduction 1 37

Psilocybin is studied as a classic psychedelic and a novel antidepressant which induces potent changes to 38 consciousness, alongside with lysergic acid diethylamide (LSD) and dimenthil triptamine (DMT) and other 39 related chemicals of similar effects. Psilocybin's active metabolite psilocin is a non-selective serotonin 40 5-HT receptor agonist and SERT inhibitor (Dinis-Oliveira, 2017; Rickli et al., 2016). The antidepressant 41 effect of a psychedelic dose of psilocybin has a rapid onset and sustained duration (R. Carhart-Harris 42 et al., 2021; Davis et al., 2021; Griffiths et al., 2016; Yu et al., 2022). Evidence from animal research sug-43 gests that these effects relate to lasting increased synaptogenesis and transient (<week) downregulation 44 of 5-HT_{2A} receptors (Raval et al., 2021) in the hippocampus and prefrontal cortex. The antidepressant 45 effect was previously associated with the magnitude of alterations to cognition, emotion, and perception 46 (Roseman et al., 2018) induced by agonisation specifically of the 5-HT_{2A}-Gq/11 receptors (Wallach et 47 al., 2023), however, complete remission in a treatment-resistant depression patient after single-dose of 48

⁴⁹ psilocybin and pretreatment with a 5-HT_{2A} occupant trazadone was reported (Rosenblat et al., 2023), ⁵⁰ suggesting that psychedelic experience may be a useful marker of intensity of the experience, but not ⁵¹ necessary for the long-term effects. The acute experience is accompanied by an increase in body tem-⁵² perature, heart rate, and blood pressure with return to normal within 12 hours (Holze et al., 2022). ⁵³ Early evidence suggests that increase in blood pressure and heart rate may be a marker of antidepressant ⁵⁴ response (PhD Thesis, Andrashko).

Subjective psychedelic experience is generally characterised by intense changes in perception, emotion, 55 and cognition, changes usually perceived as positive (Studerus et al., 2011). These changes are occa-56 sionally accompanied by feelings of dysphoria and panic in high doses, and show potential to be resolved 57 towards positive outcomes when occurring in supportive setting (Kluckova et al., 2024; Studerus et al., 58 2011). Clinical use of psilocybin does not lead to subsequent drug abuse or increased incidence of mental 59 health problems (Krebs & Johansen, 2013; Studerus et al., 2011). Intensity of psychedelic experience 60 is captured by an Altered State of Consciousness questionnaire (ASC; Dittrich, 1998). The main axes 61 of the experience are oceaninc boundlessness (OBN), anxious ego-dissolution (AED), and visionary re-62 structuralization (VIR). Generally OBN captures the mystical nature of the experience, VIR captures 63 the hallucinatory part, whereas AED captures the aspects of a 'bad trip'. The limitation of the ASC is 64 that it provides a narrow retrospective narrative of the experience void of personal process (Preller & 65 Vollenweider, 2018). 66

Electroencephalography (EEG) captures the electrical activity generated by large groups of neurons, offers 67 a convenient, cost-effective, user-friendly, noninvasive method with high temporal resolution suitable for 68 capturing changes in brain activity in humans. Bravermanová et al., 2018 show that acute intoxication 69 with psilocybin affected early perceptual (p100) and higher cognitive (p300) processes and that the size 70 of this effect correlated with the individual intensity of the experience but that pre-attentive cognition 71 was not affected. The study of a resting-state (task-free activity), usually described in terms of neural 72 synchrony (power and functional connectivity) and predictability (signal complexity) shows that the 73 psychedelic state is hallmarked by a suppression of alpha (8-12Hz) power spectral density acutely (in 74 psychedelics, in general, Pallavicini et al., 2019, in psilocybin accompanied by a theta desynchronization 75 Ort et al., 2023), an increase in functional connectivity post intoxication (in the Default Mode Network 76 (DMN), Kuburi et al., 2022), and an increase in brain signal diversity (Lempel Ziv complexity LZc; 77 Lempel and Ziv, 1976, LSD, Mediano et al., 2020, DMT Timmermann et al., 2019, psilocybin M. M. 78 Schartner et al., 2017). Psilocybin modulates perceptual and higher-order activity to be more diverse 79 and unpredictable while preserving complex causal functioning (Bravermanová et al., 2018; Ort et al., 80 2023). 81

It is made available under a CC-BY-NC-ND 4.0 International license .

4

1 INTRODUCTION

Capturing progressive changes induced by the onset and duration of the psychedelic experience showed 82 power spectral density desynchronization (delta 0-4Hz, alpha 8-13Hz, and gamma 30-45Hz) dependent 83 on plasma levels, but changes in complexity (LZc) peaked after the intensity of experience started to 84 recede (DMT; Timmermann et al., 2023). Sensitivity of LZc to changes lasting beyond the acute 85 intoxication may be explained as relating to changes in thought pattern often reported by participants 86 after a psychedelic experience (Mason et al., 2019). LZc is dependent on level of interaction with 87 environment; increase in LZc was the largest in an eves-closed resting-state condition compared to music 88 condition, eyes open, and TV watching; activities which also increase brain entropy, but this increase 89 was not as pronounced under LSD when compared with placebo (Mediano et al., 2024). Considering 90 the visual nature of psychedelic experience especially in eyes closed condition, together with that visual 91 stimulation increases Lempel-Ziv diversity (Orłowski & Bola, 2023), it may be that changes induced 92 by psychedelics turn trivial stimulation into vivid experiences, an effect pronounced particularly in the 93 absence of any stimuli (Kometer & Vollenweider, 2018; Wießner et al., 2021). Complexity via State-94 Space Entropy Rate (CSER) is a novel measure analogical to LZc, which allows the study of brain signal 95 diversity across functional bands, thus crossing the bridge between LZc, and classical power analysis. 96 Mediano et al., 2023 show that the effect of psychedelics on brain entropy is mostly in the fast oscillating 97 gamma band (> 25Hz), associated with higher order activity. 98

The continual changes in brain activity have insofar not been tested under psilocybin using EEG. We 99 expect to see changes in absolute power, relative power spectral density, mainly in the alpha (8-12Hz). 100 We expect to see changes in brain signal complexity extended beyond the acute effects, and that these 101 changes will be mostly in the gamma frequency. We expect a global desynchronisation. We expect to 102 find an increase in LZc. We expect the magnitude of these changes to correlate with the intensity of the 103 experience measured by ASC, particularly with changes in the DMN. Acute effects should be accompanied 104 by a transient changes to heart rate but not heart rate variability. An exploratory attempt will be made 105 at relating EEG measures to the intensity of the experience, and at correlating the GFC and CSER. 106

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1: Study timeline: current study was a part of a larger clinical trial with many research caveats. From Kluckova et al., 2024

107 2 Methods

¹⁰⁸ 2.1 Study approval

The study was approved by the Ethical Committee of the National Institute of Mental Health (NIMH–CZ),
 by the State Institute for Drug Control, and as a clinical trial registered under the EudraCT No. 2012 004579–37.

112 2.2 Experimental design

In a double-blind, placebo-controlled crossover design, all participants took part in active and placebo sessions, which were a minimum of 28 days apart (thought to remove any subacute effects or afterglow of psilocybin Aday et al., 2020; Evens et al., 2023; Studerus et al., 2011, an average of 67.55 days apart, SD = 69.53). This experiment had two arms: EEG and fMRI (see fig. 2.2). The current experiment was part of the EEG arm and was not affected by the fMRI arm that followed. As the EEG arm always preceded the fMRI arm, participants were unblinded to which arm they were participating in.

It is made available under a CC-BY-NC-ND 4.0 International license .

6

2 METHODS

The order of drug administration, gender, and order of drug/placebo administration was randomized in 119 5 balanced blocks of 4 participants. Psilocybin and placebo capsules were prepared by an independent, 120 unblinded pharmacy. Each session began with a short examination of participants, assuring the exclusion 121 of acute contraindications for participation. This included somatic examination, questions about a current 122 life situation, blood pressure, and heart rate, and a negative result of alcohol breathalyzer and urine rapid 123 drug tests for main drug classes. The session was held in a living room-like decorated experimental room 124 inside a Faraday cage where subjects spent most of the experiment. During the session, they were always 125 accompanied by a gender-balanced team of two sitters, one of whom was always a psychiatrist. The 126 study nurse was also present in a neighboring room throughout the session. 127

Participants slept at the clinic for habituation. On the morning of the experimental days (around 9 am), psilocybin was administered orally on an empty stomach with 200 ml of water in 1 and 5 mg capsules in a dosage adjusted to body weight (1 mg per 5 kg, range 15–22 mg, mean = 18.35 mg, SD = 2.21 mg). Psilocybin-induced psychedelic effects last approximately 6 hours. A standardized music playlist was played throughout most of the session and was paused for the EEG recording. Approximately 9 hours after the dosing, participants went to sleep in a sleep lab.

134 2.3 Participants

Twenty healthy volunteers (10 M/10F, mean age = 36, SD = 8.1, range 28 - 53) took part in the study 135 as part of a larger clinical trial registered under EudraCT No. 2012-004579-37 (major inclusion criteria 136 are in appendix A.1, for full recruitment, screening, and procedure details see Viktorin et al., 2022). 137 Subjects were recruited from November 2017 to July 2018 via a peer-to-peer method and pre-screened 138 via phone or email interview to exclude those who did not meet the major inclusion criteria. Those 139 that met the major screening criteria were invited to an introductory meeting. During a two-hour-long 140 interview, participants were informed in detail about the nature of the study, the drug effects, and safety. 141 They were free to ask questions related to the experiments or psilocybin. All participants provided written 142 informed consent before they entered the study. Subjects were screened by the Minnesota Multiphasic 143 Personality Inventory (MMPI-2, Butcher et al., 1991) and Mini-International Neuropsychiatric Interview 144 (MINI, Sheehan et al., 1998) for any significant psychopathology. The study design corresponded to the 145 Guidelines for Safety in Human Hallucinogen Research (Johnson et al., 2008). Participants were asked to 146 abstain from drug use during the period between the interview and the experiment, alcohol use leading 147 to drunkenness (1 week), coffee and food (in the morning), and tobacco (2 h) before the experiment. 148 One participant was excluded due to excessive daytime sleepiness (recognized during the placebo EEG 149 session). To avoid interactions with the menstrual cycle, women were not dosed during their menses (see 150

It is made available under a CC-BY-NC-ND 4.0 International license .

2.4 EEG aquisition

¹⁵¹ Dudysova et al., 2020 for details).

152 2.4 EEG aquisition

¹⁵³ 20 participants were included in the study. One participant did not arrive to the second session. 4 ¹⁵⁴ recordings had to be excluded for non-systematic mistakes including detached reference electrode (2), a ¹⁵⁵ mistake during saving the recording (1), and one missing file. Data were excluded element-wise, resulting ¹⁵⁶ in 230 data entries included in the analysis.

157 2.5 Psilocybin dose

Psilocybin was manufactured according to good manufacturing practice standards from THC-Pharm GmbH, Frankfurt, Germany. Gelatine capsules containing 1 and 5 mg of psilocybin homogenized with *Trittici amylum* were prepared in the pharmacy of the Institute for Clinical and Experimental Medicine in Prague, Czech Republic. The dose was set to be approximately 0.26 *mg/kg*, an intermediate psychedelic dose (Nichols, 2016; Tyls et al., 2016), and was adjusted by 1mg per each 5kg of body weight. The drug was administered orally in an adjusted number of capsules and swallowed with drinking 200 mL of water.

¹⁶⁵ 2.6 Acute psychedelic state

The Brief Psychiatric Rating Scale (BPRS), commonly used for a brief evaluation of psychiatric symptoms by a clinician, informs about the absence, presence, and severity of symptoms that include anxiety, depression, hostility, grandiosity, hallucinations, and unusual thought content (for full details, see Overall and Gorham, 1962). In the context of our trial it is used to rate the intensity of the clinically relevant psychological impact of psilocybin across the session at baseline, 1-, 3-, and 6-hours after (Figure 4). Participants were evaluated by a psychiatrist-rater blinded to the treatment condition.

The Altered State of Consciousness Questionnaire (Dittrich, 1998) is used to retrospectively evaluate the intensity of altered state of consciousness along three axis: Oceanic Boundlesssness (OBN), Anxious Ego Dissolution (AED), and Visionary Restructuralisation (VIR). Generally, OBN refers to the positive experiences of loss of boundaries and experience of unity, AED refers to the negative experiences usually related to anxiety and loss of control, and VIR captures extent to which the experience is unusual on sensory level. A revised version of the ASC, the 5d ASC includes psychedelic specific axes Auditory

It is made available under a CC-BY-NC-ND 4.0 International license .

8

2 METHODS

Alterations and Vigilance Reduction (for full details see Preller and Vollenweider, 2018. In the current study, the questionnaire was used in it's original form.

180 2.7 EEG setup, recording intervals

A high-density equidistant 256-channel gel cap (HydroCelTM, Geodesic Sensor Net 256-channel used with 181 EGI Net Amps) was applied by an EEG technician. EEG recordings took place in the EEG experimental 182 room (Faraday cage), with a battery-powered EGI system (EGI NetAmp GES 400 with FICS box) sampled 183 at 1000 Hz. Each recording commenced with a measurement of impedance and electrode readjustment 184 to minimize impedances. A 5-minute-long recording of resting state task-free eyes closed spontaneous 185 activity in a semi-reclined or reclined position was obtained at baseline (prior to psilocybin/placebo 186 ingestion) and post ingestion at 1-, 1.5-, 3-, 6-, and 24-hours intervals (see fig. 2.2 for a full protocol). 187 Music was stopped during the resting-state recordings. The EEG cap was mounted at baseline, and kept 188 through the 1-, 1.5-, 3-, and 6-hours data acquisition points. After 24-hours was data was acquired with 189 a newly mounted cap. 190

¹⁹¹ 2.7.1 Data pre-processing

Pre-processing was performed using the BrainVision Analyzer ("BrainVision Analyzer (Version 2.2.2), 192 Gilching, Germany: Brain Products GmbH.", 2021) for all 230 acquired recordings. Data sampled 193 at 1000Hz was band-pass filtered between 0.5 and 250Hz using an IIR filter, with a notch filter at 194 50Hz. Continuous data was visually inspected by an EEG expert; gross artifacts were marked as bad 195 segments. An Independent Component Analysis was used to remove eye artifacts (horizontal and vertical 196 eye movements) and ECG - ECG channel was included in the component calculation estimate. Sleep 197 specialist marked epochs of sleep, drowsiness, and reduced vigilance. If more than 60% of the signal had 198 to be removed due to artifacts or sleep, or if more than 4 independent components had to be removed. 199 recording was removed from the analysis. Data was parceled into 4 second epochs with 1 second overlap 200 and re-referenced to an average reference. This data was exported as continuous EEG data files and 201 used in further analysis. 202

203 2.7.2 Electrocardiogram

ECG was recorded and used to subtract ECG artifact from the EEG signal. QRS peaks were detected using an inhouse python script. Heart rate (HR) and heart rate variability (HRV) obtained from the

It is made available under a CC-BY-NC-ND 4.0 International license .

2.7 EEG setup, recording intervals

²⁰⁶ peaks to compare between conditions across times.



207 2.7.3 EEG Measures

Figure 2: Electrodes divided by brain regions. Left
and right hemisphere were divided at the central line.
Image from M. Schartner et al., 2015.

Absolute power was calculated using the fast Fourier transformation from the 4 second segments further split into 2 second segments to achieve 0.5Hz accuracy, using the compute psd function with multi-taper option and frequencies of interest 1 to 100hz, included in the MNE library. The median was computed across epochs and channels. The % difference from baseline was computed. Further, baseline distribution of power within frequency bins were used to calculate Z score normalised changes from baseline for each participant. This step also serves to aid visual inspection of data as it removes the 1/frequency power distribution. Finally, Z scores were averaged using the median, and placebo condition was removed from psilocybin condition.

Relative power was computed from the absolute power to assess the changes in spectra composition. 224 Data were divided into the functional bands delta 1-4Hz, theta 4-8Hz, alpha 8-12Hz, beta 13-25Hz, 225 and gamma 25-45Hz. Summative power in each band was divided by the total broadband energy, 226 normalising the power to values between 0 and 1. Cluster analysis was conducted between Placebo and 227 Psilocybin to assess the changes in EEG bands in time with permutation based correction for multiple 228 comparisons. Alpha peak frequency with maximum energy was identified to analyse shift in alpha peak 229 across conditions and times. To account for possible variation outside of the functional band, area from 230 6 to 15Hz was searched for maximum relative power value. Baseline subtracted values were then fitted 231 to a Linear Mixed Model. 232

Functional connectivity power envelope correlation was computed on orthogonalised time series FIR band pass filtered to EEG functional bands, computing the power envelopes using the Hilbert transform, then computing the correlation matrices using the mne_connectivity package. Orthogonalisation was done pairwise. Correlation matrix was averaged to obtain an average correlation from each electrode to all other electrodes (global functional connectivity, GFC), and GFC was averaged over the frontal,

It is made available under a CC-BY-NC-ND 4.0 International license .

10

2 METHODS

²³⁸ parietal, and occipital areas laterally, and over RSNs on source localised data.

Lempel Ziv (LZ) signal diversity was calculated using the LZ76 algorithm. The algorithm was applied
 to 4-seconds segments Z-scored EEG downsampled to 250Hz data, then averaged channels, and over
 epochs, to avoid concatenation. LZ scores were normalised to obtain entropy rate.

Complexity via State Space Entropy Rate (CSER) was calculated analogically to LZ (for methodology see Mediano et al., 2023) on Z-scored EEG time series downsampled to 250Hz, then integrated over the EEG functional bands. The benefit of such band decomposition is that the summation of the parts is equal to the broadband entropy, which would not be the case if data were filtered before the CSER calculation.

247 2.7.4 Source Localisation

Source localisation was applied to pre-processed 248 data using beamformer solution implemented in 249 the Matlab Fieldtrip (Oostenveld et al., 2011). 250 The LCMV method was used to obtain virtual 251 sensors in the 90AAL atlas source-space (Rolls 252 et al., 2020; Tzourio-Mazoyer et al., 2002), us-253 ing an average BEM conduction model, and gen-254 eral channel locations for the HydroCel Geodesic 255 256-channel Sensor Net. Results from source de-256 composition were in statistical analysis averaged 257 over 3 functional networks, Frontoparietal network 258 (FPN), Default Mode Network (DMN), and the 259 Visual Network (VIS) according to Oliver et al., 260 2019, and remaining space (Other, for reference 261 see fig. 3). 262



Figure 3: Resting state networks in the AAL90 space.

263 2.7.5 Statistical analysis

Questionnaires were analysed using a t-test. Linear mixed effects models (LMM) were fit to normalised measures of EEG activity using the Ime4 library for R, and the linear mixed effects models included in the statsmodels library for Python. Fixed effects of condition with two levels of psilocybin and placebo with

It is made available under a CC-BY-NC-ND 4.0 International license .

2.7 EEG setup, recording intervals

the random effects of subject and time were included in the analysis. Analysis of variance was used to interpret results of LMM modelling. False discovery rate of 5% was maintained by adjusting all *p* values using the *p.adjust* function included in R language. Thus 5% of significant results is expected to be truly null, with the exception of the permutation based cluster analysis of relative EEG power, where missing data were removed pair-wise (for each condition across levels of time), and probability is adjusted to it's permuted distribution.

273 2.7.6 Exploratory analysis

In an attempt to relate different measures of the EEG signal together, we explored the changes of EEG measures in the DMN, and intensity of subjective experience measured by the ASC. Further, to relate brain synchrony and unpredictability, we correlated the GFC and CSER across regions and EEG functional bands. Exploratory analysis was not included while controlling for multiple comparisons.

It is made available under a CC-BY-NC-ND 4.0 International license .

12

3 RESULTS

278 3 Results

279 3.1 State of consciousness

The brief psychiatric rating scale (BPRS; Overall and Gorham 1962) revealed that participants were experiencing non-normal symptoms at 1 and 3 hours after intoxication, and were back to normal at 6 hours after dosing (Figure 4A., asterisks denote levels of significance). The 4B. shows that participants retrospectively reported a significant difference along the three main axes of Altered State of Consciousness scale (FDR corrected).

²⁸⁵ 3.2 ECG: Heart rate and Heart Rate Variability

No difference between groups was observed between levels of condition psilocybin/placebo, or across time, that could not be attributed to random fluctuations in heart rate and heart rate variability. Percentage change from baseline is viewed in fig. 4 for individuals and group averages with standard error rates to account for differences between individuals.

²⁹⁰ 3.3 EEG absolute and relative power

Absolute power average increase is observed in both low and high frequencies both in psilocybin and 291 placebo condition, with the exception of alpha and low beta frequency at 1 and 1.5 hours in the psilocybin 292 condition, where power is below the baseline, and a broadband decrease except at alpha peak 24 hours 293 after. Broadband increase is visible in both conditions, particularly at 6 hours. Percentage change from 294 baseline absolute power group average is shown in 4D. Figure 5 shows that increase in delta and gamma 295 is localised in temporal electrodes. Z-score changes from baseline per participant are in fig. 6 A., showing 296 decrease in alpha and beta; effect size reaching significance at 1, 1.5 and 3 hours, and significant increase 297 in delta and gamma frequencies, after temporal channels were removed. A median group difference is 298 present in fig. 6B. where size of effect reaches significant decrease at 1.5 hours in alpha and beta at 3 299 hours, and shows a trend toward a decrease at 3 and 6 hours, and a broadband decrease at 24 hours (Z 300 score of $> \pm 1.96$). 301

Relative power obtained for each individual representing spectral composition was compared between psilocybin and placebo groups and between functional bands (delta 1-4Hz, theta 4-7Hz, alpha 8-12Hz, beta 13-25Hz, gamma 25-45Hz) at 6 time points computing a two-tailed permutation analysis ($\alpha =$

It is made available under a CC-BY-NC-ND 4.0 International license .

3.4 Global Functional Connectivity

13

³⁰⁵ 0.05). Temporal channels known to include a lot of muscle artifacts were excluded from the analysis (see ³⁰⁶ fig. 5 and fig 2).

Individual relative power is shown in figure 7. A drop in relative power from baseline in the alpha band
can be seen in two participants (PSI025 and PSI026) with return to normal at 3 hours. We observed
a significant reduction in power in the psilocybin condition in the Alpha band at 1, 1.5, and 3 hours
compared to placebo. At 3 hours, we also observed a significant decrease in beta activity frontally (fig.
8b, relative power, cluster analysis).

312 3.4 Global Functional Connectivity

The GFC shows mainly a whole brain decrease in connectivity in the alpha band at 1 and 1.5 hours, 313 and a decrease parietally in the beta frequency at 1 hour in psilocybin group. In placebo, an increase in 314 delta band at 6 hours frontally and at 1.5 hours parietally is observed. Inverted individual difference from 315 baseline, and group averages are shown in fig. 11 with error bars and asterisks marking FDR corrected 316 significant difference obtained from an LMM model. Fig. 16A. shows GFC averaged over the source 317 reconstructed space, baseline removed. Significant results of the LMM model did not survive correction. 318 A trend towards a decrease was observed in alpha at 1 and 1.5 hours globally, and an increase in the 319 DMN in the gamma band at 1 hour. Note that while significant group differences were observed in 320 the alpha, beta, and gamma band, the opposite effect on individual level is also visible. Further, in the 321 placebo condition, changes from baseline of similar magnitude can occur. 322

323 3.5 Entropy measures

324 3.5.1 Lempel Ziv Complexity

LZ signal diversity showed increase at 1 hour in the parietal lobes. When averaged over the 3 functional networks in the AAL90 space, significant increase in entropy is observed in the psilocybin condition, mainly in the default mode network and the visual network. A significant decrease in entropy is observed for the duration of the experiment in the placebo condition, particularly in the default mode network, see fig. 13.

It is made available under a CC-BY-NC-ND 4.0 International license .

14

3 RESULTS

330 3.5.2 Complexity via State Space Entropy Rate

Psilocybin reduced CSER complexity in the alpha band globally at 1 to 3 hours, and an increased 331 broadband complexity at 1h parietally and in the right frontal lobe. In the placebo condition, a decrease 332 was observed in the delta band (fig 14). Analysis over functional networks in the source-space revealed 333 that complexity decreased in the alpha band in the visual network and rest of the brain at 1 to 3 hours, 334 in the frontoparietal network at 1 and 1.5 hours, and at 1 hour in the DMN. A significant increase in 335 complexity from 1 to 6 hours is observed in the gamma band in the visual cortex. In the placebo group, 336 an increase in complexity is seen in the placebo group in the FPN cortex in alpha and beta, and a decrease 337 in the DMN at 1, 3, and 6 hours broadband. Interestingly, in the visual cortex, there is a significant 338 increase at 3 & 6 hours in the alpha, but a decrease in gamma (15). 339

340 3.5.3 EEG measures in the DMN and subjective experience

Changes in default mode network from baseline were explored. Only the change from baseline in gamma GFC in DMN at 1 hour showed a moderate significant relationship between intensity of subjective experience represented by the Oceanic Boundlessness. Due to low variability and the floor effect in the placebo condition, this needs to be interpreted with caution. We also correlated changes in other functional bands in the DMN with OBN, but these were not significant and we do not report them.

346 3.5.4 GFC and CSER

Fig 16 shows the relationship between absolute values of CSER and GFC at different time points and across functional bands, with Pearson correlation and associated p-value, uncorrected. Note that the x scale differs for each EEG band.

It is made available under a CC-BY-NC-ND 4.0 International license .

3.5 Entropy measures



Figure 4: **A**. The BPRS used to evaluate mental state objectively shows significant departure from normality at 1 and 3 hours. **B**. The ASC retrospective assessment of the experience shows sig. difference between groups along the three main subscales. Note the overlap between the groups in 10% of cases. **C**. shows that heart rate and heart rate variability did not differ between the groups significantly at any time point, change from baseline displayed. **D**. shows descriptive change from baseline of absolute EEG power between 1 to 100Hz. X axis is log scaled. The large differences between delta and gamma were explored further (see fig. 5.)

It is made available under a CC-BY-NC-ND 4.0 International license .

3 RESULTS



Figure 5: The topographical maps of median group activation in delta and gamma frequencies. The activation is from activity recorded under electrodes on the cheeks. Median is displayed as mean was affected by single electrode (outlier) activation. Temporal electrodes were excluded from further group statistical analysis (see fig. 2).

It is made available under a CC-BY-NC-ND 4.0 International license .

3.5 Entropy measures



Figure 6: A. Z score change from baseline in Psilocybin and Placebo. Most prominent changes are decrease in alpha and beta activity. B. Difference between Psilocybin and Placebo group shows significant increase in high frequency synchronisation and trend towards a decrease in alpha and beta bands during intoxication. At 24 hours there is a trend towards a decrease in absolute power. Values further than absolute distance of 1.96 from zero are associated with p < 0.05.

It is made available under a CC-BY-NC-ND 4.0 International license .

3 RESULTS



Figure 7: Relative power across conditions and times describe frequency energy composition changes for each individual.

It is made available under a CC-BY-NC-ND 4.0 International license .

3.5 Entropy measures



Figure 8: A. Group average relative power spectral composition across time shows drop in alpha EEG functional band (8-12Hz) at 1, 1,5, and 3 hours. B. Relative power spectral density permutation based cluster analysis shows changes in relative power distribution. Compared to placebo, a significant reduction frontally, parietally and occipitally occurred at 1, 1.5, and 3 hours. Reduction in Beta was observed at 3 hours. Full red mark significance at p < 0.01 and hollow red marks at p < 0.05. Topomaps show us a trend towards an increase in delta, and gamma bands at 1-3hours. T values shown.

It is made available under a CC-BY-NC-ND 4.0 International license .

3 RESULTS



Figure 9: Change from baseline **Alpha peak** across conditions and times for each individual. No significant difference from baseline was observed, likely due to the opposing effects on each individual.



Figure 10: Source localisation of changes from placebo in **A. alpha band at 3 hours** post ingestion shows reduction in alpha EEG functional band (8-12Hz) activity in the right hemisphere Occipital superior and middle, Cuneus, Calcarine areas. **B. Beta band at three hours** shows decrease in activity mainly in Postcentral, Precentral, and Parietal Inferior left hemispheric areas and Frontal Superior on the right side.

It is made available under a CC-BY-NC-ND 4.0 International license .

3.5 Entropy measures



Figure 11:

Change from baseline in **Power Envelope GFC** across functional frequencies averaged over frontal, parietal, and occipital regions laterally shows significant decrease from baseline in connectivity globally at 1 and 1.5 hours, and frontally also at 3 hours in the psilocybin group. On the right parietal lobe we also see decrease in beta at 1 hour, and in the placebo group we see an increase in delta activity.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 12:

A.Change from baseline in **GFC RSNs** across functional frequencies. Comparisons did not survive FDR correction. We see a trend towards a decrease in all networks in alpha band at 1 & 1.5 hours, and an increase in gamma in DMN at 1h. **B. Change in GFC from Baseline in DMN gamma band** shows a moderate Pearson correlation between magnitude of change, and intensity of oceanic Boundlessness subscale of the altered states of consciousness.

It is made available under a CC-BY-NC-ND 4.0 International license .

23

3.5 Entropy measures



Figure 13: Change from baseline **Lempel-Ziv Complexity** normalised entropy rate shows rapid increase in entropy at 1 hour parietally. In the source-space, increase in entropy is observed in the psilocybin group at 1 hour in the frontoparietal network, at 1, 1.5, and 6 hours in the Default Mode Network, and 1, 1.5, and 3 hours in the Visual Network, and 1, and 3 hours in the rest of the brain. In the placebo condition, a drop in complexity is seen from 1 to 6 hours in the default mode network, and 3 and 6 hours in the visual network.

It is made available under a CC-BY-NC-ND 4.0 International license .

3 RESULTS



Figure 14: Change from baseline **Complexity via State Space Entropy Rate** shows a distinct change in psilocybin condition a decrease in alpha band at 1, 1.5, and 3 hours globally, and an increase at 1 hour parietally, and frontally on the right hemisphere. Broadband CSER shows similar results to LZ, and an opposing effects of psilocybin on alpha and broadband entropy, and further that entropy is mostly driven by higher frequencies. A decrease in entropy in the placebo condition is observed parietally and on the frontal and occipital left hemisphere. Note different scales on the Y axis.

It is made available under a CC-BY-NC-ND 4.0 International license .

25

3.5 Entropy measures



Figure 15: Change from baseline **Complexity via State Space Entropy Rate** normalised entropy rate over source-space functional networks shows a decrease in entropy mainly over the visual network at 1-3 hours in the alpha band, and an increase in gamma and higher frequencies. Interestingly, we can observe an increase in CSER in the alpha and beta band in the frontoparietal network, and a decrease in the default mode network and visual network in the broadband.

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 16: Functional band decomposition **correlation between GFC and CSER**. From left, weak negative relationship appears to be in delta, weak positive relationship in theta, but in alpha a weak positive relationship arises during the 1-3 hours, suggesting that psilocybin alters this relationship, and an opposite relationship is present in gamma. In beta, a weak positive relationship appears at 6 and 24 hours. Pearson correlation calculated, uncorrected. Lines represent general linear models.



It is made available under a CC-BY-NC-ND 4.0 International license .

350 4 Discussion

In a cross-over design, we compared placebo with 0.26mg/kg of psilocybin administered orally (20mg in 351 77kg person), a low to moderate dose. Healthy subjects experienced significant alteration to the normal 352 state of consciousness on sessions when they received psilocybin compared to placebo. Changes started 353 within 1 hour, and were back to normal levels at 6 hours (fig 4 A. and B.). These alterations did not 354 result in significant changes to the heart rate and heart rate variability (fig 4 C.) but resulted in changes 355 in EEG activity (fig 4 D.). In accord, Holze et al., 2022 shows that low dose of psilocybin (15mg) lasted 356 app. 4 hours, whereas high dose (30mg) lasted app. 7 hours, that the low dose did not cause changes 357 in the heart rate but the high dose did. 358

Absolute EEG power increased in high (gamma) and decreased in alpha and beta frequencies compared 359 to placebo during the session, and 24h after dosing there is a trend towards a decrease broadband (see 360 figs. 4D., and 6). Changes in delta and gamma were induced by activation in peripheral electrodes 361 (fig. 5) likely originates from jaw clenching rather than from neural activity, and temporal channels were 362 removed from further analysis. An increase in low and high frequencies was present in both placebo 363 and psilocybin conditions, and may be associated with setting of EEG gel, and galvanic skin response to 364 the warm conditions inside the Faraday cage. Broadband power desynchronisation after psilocybin was 365 observed previously in rodents (Tyls et al., 2016), and in humans with psychedelics in general (Le et al., 366 2024). 367

Analysis of relative power composition showed that psilocybin administration resulted in attenuation in 368 the alpha band at 1 hour, 1.5 hours, and 3 hours globally and an attenuation in beta band frontally (fig 369 7 and 8). Source reconstruction localised sources of the decrease at 3 hours in alpha band mainly on 370 the right hemisphere in the occipital superior and middle, and the cuneus and calcarine areas. In the 371 beta band the decrease was mostly in the postcentral, precentral, and parietal inferior areas on the left 372 hemisphere, and in the frontal superior right area (fig. 10). Attenuation in the alpha band activity is a 373 robust trait of a psychedelic state associated with visual experience of imagery, seeing with eyes-closed 374 (R. L. Carhart-Harris et al., 2016; De Araujo et al., 2012), which may be caused by deficient thalamic 375 gating in the pulvinar (Preller et al., 2019) affecting activity in the V1. We did not observe a shift in 376 the alpha peak under psilocybin, our data shows that some individuals experience quickening and some 377 slowing of the alpha activity (fig 9). We observe a significant decrease in beta spectra at 3 hours (fig. 378 8). It is intriguing that this effect is temporarily localised to three hours, even though a trend towards 379 this is observable at 1 hour as well. The desynchronisation of the frontal beta activity may generally 380 be associated with inability to maintain focus, perform cognitively demanding tasks, and from inability 381 to suppress thoughts (Bonnieux et al., 2023; R. L. Carhart-Harris & Friston, 2019). From our data we 382

It is made available under a CC-BY-NC-ND 4.0 International license .

28

4 DISCUSSION

may conclude that psilocybin becomes active first in the occipital regions, then in the frontal regions, experienced as intense visual stimulation only later followed by change in cognition.

The global functional connectivity (GFC) revealed a significant decrease in connectivity from baseline 385 globally in the alpha band at 1 and 1.5 hours, and at 3 hours frontally (fig 11), and a decrease in 386 beta GFC at 1 hour parietally. Comparing groups on GFC across RSNs did not survive FDR correction, 387 however a trend towards a decrease in alpha band and an increase in gamma band is visible (fig. 12 388 in the DMN). It has been shown that psilocybin produces broadband desynchronisation of activity in 389 MEG signal (Muthukumaraswamy et al., 2013). Siegel et al., 2023 report similar findings from fMRI 390 blood oxygen level dependent (BOLD) signal, that the decrease is mainly in the Default Mode Network. 391 R. L. Carhart-Harris et al., 2013 show that the functional connectivity from DMN is however increased 392 to task positive networks as a result of psilocybin, a relationship which is orthogonal otherwise. Decrease 393 in GFC may reflect two things. Firstly, decrease in information processing overall, or, secondly, increase 394 in information processing locally. Because power increased, but GFC decreased, it may be deduced that 395 information processing did not cease, but became segregated as a function of psilocybin. Decrease in 396 GFC is associated with cognitive decline (e.g. (Onoda et al., 2012)), but coupled with known effects of 397 psilocybin, it may reflect impairment in cognitive functioning perhaps due to over-integration of over-398 salient stimuli. In other words, inability to focus by being distractable by external and internal processes 399 (R. L. Carhart-Harris et al., 2011). 400

If stimulus integration into neural activity is segregated, i.e. processed locally, then the brain activity 401 would reach more uncoordinated neural states, which would increase the complexity of the EEG traces. 402 Analysis of signal diversity using the Lempel-Ziv (Lempel & Ziv, 1976) algorithm shows an increase at 1 403 hour parietally. However, a significant increase in LZ is observed in the visual network at 1 to 3 hours, 404 in the DMN at 1, 1.5, and 6 hours, and in the frontoparietal network at 1 hour. Increase in LZ was 405 reported in LSD condition (Mediano et al., 2024), DMT (Timmermann et al., 2023) and Psilocybin 406 (M. M. Schartner et al., 2017). But an increase in LZ is also associated with changes in information 407 processing due to acupuncture (Luo et al., 2012) and after processing complex visual and auditory 408 stimuli (Orłowski & Bola, 2023). Thus, LZ may increase when the brain is trying to interpret a not-409 easily interpretable stimulus. When psychedelics increase brain segregation, the brain struggles to process 410 information locally. This may be represented psychologically by experiences of novelty. Interestingly, we 411 also observe a decrease in signal diversity in the placebo condition mainly in the default mode network 412 from 1 to 6 hours, and the visual network at 3 and 6 hours (fig 13). From perspective of stimulus 413 integration, this may be explained as a habituation to the study conditions. Changes in the visual area 414 thus may be associated with vivid imagery, whereas changes to DMN may reflect perception of self; a 415 process which may be heightened in the psilocybin condition, but relaxes over time under in placebo 416

It is made available under a CC-BY-NC-ND 4.0 International license .

29

417 condition.

Complexity via State-Space Entropy Rate results show that signal diversity decreases globally under 418 psilocybin in the alpha band at 1 to 3 hours, and increases in the higher frequencies at 1 hour (see fig. 419 14), which replicates the findings of Mediano et al., 2023. CSER analysis over RSNs shows decrease 420 mainly in the alpha band in the visual network at 1 to 3 hours, and the fronto-parietal network at 1 and 421 1.5hours, and an increase in the gamma band at 1 to 6 hours in the visual network, but also a sporadic 422 increase in DMN. The visual cortex shows sensitivity to changes induced by psilocybin as measured 423 by decrease in CSER and LZ. An apparent relationship between alpha decrease and higher frequencies 424 increase in the psilocybin condition may reflect integration of stimuli behind closed eyes. In a normal 425 wake eves-closed resting state, alpha activity in the visual cortex may be interpreted as synchronisation of 426 weakly coupled oscillators receiving random input (Hidalgo et al., 2022). Complexity may be driven down 427 when the signal becomes non-random due to changes induced by psilocybin, marked by desynchronisation 428 in the alpha power spectra. However, associative processing of drug induced content may be happening 429 in higher frequencies gamma. Our findings make case for the careful study of higher brain frequencies, 430 a task difficult due to EEG artifacts. In the placebo condition, we see a significant increase over the 431 fronto parietal network from 1 to 6 hours in both alpha and beta bands, but also decreases in the higher 432 frequencies over the default mode network and the visual area; we see the opposite effect to psilocybin 433 condition, that CSER increases in alpha at 3 & 6 hours and decreases in higher frequencies (fig 15). 434 These changes are intriguing, they may reflect on processes natural to prolonged relaxation, in any case 435 different to psychedelic experience. Changes in band-specific complexity need to be studied further to 436 allow for interpretation. 437

We found a relationship between a change from baseline to 1-hour in GFC in gamma band in the DMN, 438 and subjective experience as captured by Oceanic Boundlessness sub scale of the ASC questionnaire, 439 but not for LZ or CSER. Our exploratory finding suggests that the more DMN becomes connected with 440 the rest of the brain, the more individuals experience a sense of unity. The DMN, active during passive 441 rest and mind wandering and connected to self-reference, becomes under psilocybin more functionally 442 connected with the rest of the brain, which may explain the intensity of the psychedelic experience, 443 perhaps as the self is integrated with the rest of the brain, thus effectively lowering the segregation of 444 both our sensory information, associations about the world, and self. When correlating the GFC and 445 CSER values, we find an emergent relationship during the hours of effect of psilocybin in alpha and 446 gamma bands. This emergent relationship shows that the lower the GFC, the lower the CSER in alpha, 447 and conversely the lower the GFC, the higher the CSER in gamma. If alpha activity is connected mostly 448 to processing of the visual stimuli, and gamma mostly with the higher order associations, then the intense 449 visual imagery during psilocybin are associated with less unpredictable signal, i.e. visual experience is 450

It is made available under a CC-BY-NC-ND 4.0 International license .

30

5 LIMITATIONS

⁴⁵¹ processed locally. However, the gamma has the opposite relationship, gamma signalling under psilocybin ⁴⁵² is processed locally, more segregated and more unpredictable. Our evidence may be viewed in support of ⁴⁵³ the REBUS theory that psychedelics work to relax high-level priors on both sensory and associative level ⁴⁵⁴ (R. L. Carhart-Harris & Friston, 2019), which leads to both segregation in the sensory cortex as marked ⁴⁵⁵ by decrease in power and GFC in the alpha band, but also an integration of the DMN as the high-level ⁴⁵⁶ priors are being re-addressed by propagation of bottom-up prediction-errors, as marked by the increase ⁴⁵⁷ in gamma signal complexity.

In summary, we found difference between the psilocybin and placebo group on measures of subjective 458 intensity of experience (fig. 4), and in EEG measures of Power, GFC, LZ, and CSER (see 6, 8, 11, 13, 459 15), but we observed a linear relationship only between DMN gamma GFC and subjective experience 460 (fig. 12). Two possible explanations arise, A. changes in the brain do not relate to psychological 461 intensity of experience, or B. intensity of psychological experience is not only related to dose-dependent 462 neurobiological changes captured by EEG, but also dependent on a complex pattern of personal experience 463 including immediate mood and long-term traits (Studerus et al., 2012), generally referred to as Set in 464 Set and Setting (e.g. Hartogsohn, 2016). Our findings are complementary to emerging evidence that 465 neuroimaging changes correlate with symptoms improvement in depression patients (Kuburi et al., 2022), 466 with changes in brain activity mainly in the DMN, however, these changes are insofar too insensitive to 467 use reliably as a predictor of treatment outcome. 468

469 5 Limitations

This study was part of a clinical trial. Dosage was weight dependent, which is currently not the standard. 470 Dose was administered orally, which may lead to different metabolisation speed, biasing the effects of 471 psilocybin at any given time point in a small sample. EEG measures used are sensitive to noise in the 472 signal. Techniques beyond removal of obviously affected epochs are limited. Is not the topic of this work 473 to prove that EEG gamma activity is of neural origin. We show that changes in the gamma range differ 474 across the psilocybin/placebo conditions, and that these changes should be further studied in relation to 475 psychedelics. Thus interpretation of our results should be cautious. The within subject design has limited 476 validity in an EEG study with variable length between dosages, as the EEG traces may change in time in 477 themselves and together with dependency on electrode position and impedance. Functional unblinding 478 appears problematic in all studies with psychedelics. In our case, if participants experienced psychedelic-479 like state on their first visit, they would be unblinded to the second visit. Perhaps partly because of 480 the reasons above, we observe a variation in our measures marked by that pprox 10 % of participants in 481

either group show results similar to average of the opposite group; in EEG measures and the subjective measures of intensity of experience measured by the ASC. This fosters the notion that the role of the set and setting in which such experience is meant to take place, is crucial.

485 6 Conclusion

Psilocybin affects EEG activity acutely. The dominant change is the decrease in the alpha and an increase 486 in the gamma power, followed by a decrease in beta. This decrease, a local desynchronisation, is marked 487 by the decrease in global functional connectivity. Signal complexity increased, particularly in the visual 488 area and DMN. Decomposition of complexity into functional bands shows decrease in complexity in the 489 alpha band but an increase in the gamma band. These changes are time dependent, and are likely related 490 with the relaxation of strong believes about the world, and integration of self with the environment as 491 marked by the experience of unity. We could not confirm associations between baseline values or changes 492 in magnitude of EEG measures as intensity of the psilocybin experience, except for changes in GFC in 493 DMN in the gamma band. 494

It is made available under a CC-BY-NC-ND 4.0 International license .

ACKNOWLEDGEMENTS 7

Data and Code Availability 495

The data that support the findings are available on request from the corresponding author. The data 496 are not publicly available due to privacy or ethical restrictions. 497

Author Contributions 498

TP run the study as a principal investigator. TF guided the analysis of signal complexity. MN carried 499 out the current analysis. PM assisted with computational approaches. All authors contributed to the 500 manuscript. 501

Acknowledgements 7 502

This work was supported by the Czech Science Foundation (projects 23-07578K), Czech Health Research 503 Council (project NU21-04-00307), the national budget through MEYS, LRI CZECRIN (LM2023049), 504 Long-term Conceptual Development of Research Organization (RVO 00023752), and Specific University 505 Research, Czech Ministry of Education, Youth and Sports (project 260533/SVV/2024), the Charles Uni-506 versity research program Cooperatio-Neurosciences, ERDF-Project Brain dynamics, No. CZ.02.01.01/00/22 008/00 507 Japan Science and Technology Agency via grant number JPMJPF2205, and PSYRES - Psychedelic Re-508 search Foundation. The funding sources were not involved in the study design; in the collection, analysis, 509 and interpretation of data; in the writing of the report; nor in the decision to submit the article for 510 publication.

Declaration of Competing Interests 512

The authors declare no competing interests. 513

32

511

514 A Appendix

⁵¹⁵ A.1 Appendix 1: Inclusion and Exclusion Criteria

Inclusion criteria

- 1. Men and women at the age between 18 to 65 years
- 2. Healthy volunteers with negative psychiatric anamnesis, including harmful use, abuse and addiction to addictive substances
- 3. Negative family psychiatric anamnesis without psychotic disorders to II. Generation of relatives
- a) Men and women between 29 and 65 years of age
- b) Healthy volunteers with negative psychiatric screening (psychiatric disorders MKN 10. F0.X-F99.X)
- c) Negative familiar psychiatric anamnesis in relatives up to second-degree

Exclusion criteria

- a) Pregnant women
- b) A volunteer with intracranial hypertension, severe arterial hypertension or pulmonary hypertension
- c) A volunteer after a stroke
- d) A volunteer with congestive heart failure
- e) A volunteer with a pacemaker
- f) A volunteer with a metal clamp in the head and face
- g) A volunteer with celiac disease
- h) A left-handed volunteer
- i) Any use of regular hormonal contraception except medication
- j) Person in a dependent position undergraduate students of medical faculties
- k) Persons in a dependent position students of other faculties aged less than 28 years old
- 1) Usage of any regular medication with the exception of hormonal anti-contraceptives
- m) Persons in dependent position pre-gradual medical

It is made available under a CC-BY-NC-ND 4.0 International license .

34

A APPENDIX

516 Supplementary Material

⁵¹⁷ Supplementary Material (created during production as a web link to online material).

It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES

518 References

- ⁵¹⁹ Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effects of ⁵²⁰ psychedelic drugs: A systematic review. *Neuroscience and Biobehavioral Reviews*, *113*, 179–189.
- Bonnieux, J. N., VanderZwaag, B., Premji, Z., Garcia-Romeu, A., & Garcia-Barrera, M. A. (2023).
 Psilocybin's effects on cognition and creativity: A scoping review. *Journal of Psychopharmacology*, 37(7), 635–648.
- ⁵²⁴ Brainvision analyzer (version 2.2.2), gilching, germany: Brain products gmbh. (2021).
- Bravermanová, A., Viktorinová, M., Tylš, F., Novák, T., Androvičová, R., Korčák, J., Horáček, J.,
 Balíková, M., Griškova-Bulanova, I., Danielová, D., et al. (2018). Psilocybin disrupts sensory
 and higher order cognitive processing but not pre-attentive cognitive processing—study on p300
 and mismatch negativity in healthy volunteers. *Psychopharmacology*, 235, 491–503.
- Butcher, J. N., Aldwin, C. M., Levenson, M. R., Ben-Porath, Y. S., Spiro III, A., & Bossé, R. (1991).
 Personality and aging: A study of the mmpi-2 among older men. *Psychology and Aging*, 6(3), 361.
- ⁵³² Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell,
 ⁵³³ J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for
 ⁵³⁴ depression. New England Journal of Medicine, 384(15), 1402–1411.
- ⁵³⁵ Carhart-Harris, R. L., & Friston, K. J. (2019). Rebus and the anarchic brain: Toward a unified model of ⁵³⁶ the brain action of psychedelics. *Pharmacological reviews*, *71*(3), 316–344.
- ⁵³⁷ Carhart-Harris, R. L., Leech, R., Erritzoe, D., Williams, T. M., Stone, J. M., Evans, J., Sharp, D. J.,
 ⁵³⁸ Feilding, A., Wise, R. G., & Nutt, D. J. (2013). Functional connectivity measures after psilocybin
 ⁵³⁹ inform a novel hypothesis of early psychosis. *Schizophrenia bulletin*, *39*(6), 1343–1351.
- Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagli azucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016). Neural correlates of the lsd
 experience revealed by multimodal neuroimaging. *Proceedings of the National Academy of Sci- ences*, *113*(17), 4853–4858.
- Carhart-Harris, R. L., Williams, T. M., Sessa, B., Tyacke, R. J., Rich, A. S., Feilding, A., & Nutt,
 D. J. (2011). The administration of psilocybin to healthy, hallucinogen-experienced volunteers
 in a mock-functional magnetic resonance imaging environment: A preliminary investigation of
 tolerability. *Journal of psychopharmacology*, 25(11), 1562–1567.
- Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H.,
 & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A
 randomized clinical trial. JAMA psychiatry, 78(5), 481–489.

It is made available under a CC-BY-NC-ND 4.0 International license .

36

- ⁵⁵¹ De Araujo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., de Martinis,
 ⁵⁵² B. S., Crippa, J. A., Hallak, J. E., & Santos, A. C. (2012). Seeing with the eyes shut: Neural basis
 ⁵⁵³ of enhanced imagery following ayahuasca ingestion. *Human brain mapping*, *33*(11), 2550–2560.
- ⁵⁵⁴ Dinis-Oliveira, R. J. (2017). Metabolism of psilocybin and psilocin: Clinical and forensic toxicological ⁵⁵⁵ relevance. *Drug metabolism reviews*, 49(1), 84–91.
- ⁵⁵⁶ Dittrich, A. (1998). The standardized psychometric assessment of altered states of consciousness (ascs) ⁵⁵⁷ in humans. *Pharmacopsychiatry*, *31*(S 2), 80–84.
- Dudysova, D., Janku, K., Smotek, M., Saifutdinova, E., Koprivova, J., Buskova, J., Mander, B. A.,
 Brunovsky, M., Zach, P., Korcak, J., et al. (2020). The effects of daytime psilocybin administration
 on sleep: Implications for antidepressant action. *Frontiers in pharmacology*, *11*, 602590.
- Evens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023). The psychedelic afterglow phenomenon:
 A systematic review of subacute effects of classic serotonergic psychedelics. *Therapeutic Advances in Psychopharmacology*, *13*, 20451253231172254.
- Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D.,
 Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained
 decreases in depression and anxiety in patients with life-threatening cancer: A randomized double blind trial. Journal of psychopharmacology, 30(12), 1181–1197.
- Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response: An extra-pharmacological
 perspective on psychopharmacology. *Journal of psychopharmacology*, *30*(12), 1259–1267.
- ⁵⁷⁰ Hidalgo, V. M., Díaz, J., Mpodozis, J., & Letelier, J.-C. (2022). Envelope analysis of the human alpha
 ⁵⁷¹ rhythm reveals eeg gaussianity. *IEEE Transactions on Biomedical Engineering*, *70*(4), 1242–1251.
- Holze, F., Ley, L., Müller, F., Becker, A. M., Straumann, I., Vizeli, P., Kuehne, S. S., Roder, M. A.,
 Duthaler, U., Kolaczynska, K. E., et al. (2022). Direct comparison of the acute effects of lysergic
 acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
 Neuropsychopharmacology, 47(6), 1180–1187.
- Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: Guidelines for safety. *Journal of psychopharmacology*, *22*(6), 603–620.
- Kluckova, T., Nikolic, M., Tyls, F., Viktorin, V., Vejmola, C., Viktorinova, M., Bravermanova, A., Androvi cova, R., Andrashko, V., Korcak, J., et al. (2024). The phenomenology of psilocybin's experience
 mediates subsequent persistent psychological effects independently of sex, previous experience or
 setting. *medRxiv*, 2024–08.
- Kometer, M., & Vollenweider, F. X. (2018). Serotonergic hallucinogen-induced visual perceptual alter ations. Behavioral neurobiology of psychedelic drugs, 257–282.
- Krebs, T. S., & Johansen, P.-Ø. (2013). Psychedelics and mental health: A population study. *PloS one*, 8(8), e63972.

It is made available under a CC-BY-NC-ND 4.0 International license .

- Kuburi, S., Di Passa, A.-M., Tassone, V. K., Mahmood, R., Lalovic, A., Ladha, K. S., Dunlop, K.,
 Rizvi, S., Demchenko, I., & Bhat, V. (2022). Neuroimaging correlates of treatment response with
 psychedelics in major depressive disorder: A systematic review. *Chronic Stress, 6*, 24705470221115342.
- Le, G. H., Wong, S., Badulescu, S., Au, H., Di Vincenzo, J. D., Gill, H., Phan, L., Rhee, T. G., Ho, R., Teopiz, K. M., et al. (2024). Spectral signatures of psilocybin, lysergic acid diethylamide (lsd) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. *Journal of Affective Disorders*.
- Lempel, A., & Ziv, J. (1976). On the complexity of finite sequences. IEEE Trans. Inf. Theory, 22, 75-81.
- Luo, X.-L., Wang, J., Han, C.-X., Deng, B., Wei, X.-L., & Bian, H.-R. (2012). Characteristics analysis of acupuncture electroencephalograph based on mutual information lempel—ziv complexity. *Chinese Physics B*, *21*(2), 028701.
- Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. (2019). Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being. *Journal of psychoactive drugs*, *51*(2), 123–134.
- Mediano, P. A., Rosas, F. E., Luppi, A. I., Noreika, V., Seth, A. K., Carhart-Harris, R. L., Barnett, L.,
 & Bor, D. (2023). Spectrally and temporally resolved estimation of neural signal diversity. *eLife*.
 https://doi.org/10.1101/2023.03.30.534922
- Mediano, P. A., Rosas, F. E., Timmermann, C., Roseman, L., Nutt, D. J., Feilding, A., Kaelen, M., Kringelbach, M. L., Barrett, A. B., Seth, A. K., et al. (2020). Effects of external stimulation on psychedelic state neurodynamics. *BioRxiv*, 2020–11.
- Mediano, P. A., Rosas, F. E., Timmermann, C., Roseman, L., Nutt, D. J., Feilding, A., Kaelen, M.,
 Kringelbach, M. L., Barrett, A. B., Seth, A. K., et al. (2024). Effects of external stimulation on
 psychedelic state neurodynamics. ACS Chemical Neuroscience, 15(3), 462–471.
- Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J., Brookes, M. J., Williams, T. M., Errtizoe,
 D., Sessa, B., Papadopoulos, A., Bolstridge, M., Singh, K. D., et al. (2013). Broadband cortical
 desynchronization underlies the human psychedelic state. *Journal of Neuroscience*, *33*(38), 15171–
 15183.
- ⁶¹³ Nichols, D. E. (2016). Psychedelics. *Pharmacological reviews*, 68(2), 264–355.
- Oliver, I., Hlinka, J., Kopal, J., & Davidsen, J. (2019). Quantifying the variability in resting-state networks.
 Entropy, 21(9), 882.
- Onoda, K., Ishihara, M., & Yamaguchi, S. (2012). Decreased functional connectivity by aging is associated with cognitive decline. *Journal of cognitive neuroscience*, *24*(11), 2186–2198.
- Oostenveld, R., Fries, P., Maris, E., & Schoffelen, J.-M. (2011). Fieldtrip: Open source software for advanced analysis of meg, eeg, and invasive electrophysiological data. *Computational intelligence and neuroscience*, 2011(1), 156869.

It is made available under a CC-BY-NC-ND 4.0 International license .

38

- ⁶²¹ Orłowski, P., & Bola, M. (2023). Sensory modality defines the relation between eeg lempel–ziv diversity ⁶²² and meaningfulness of a stimulus. *Scientific Reports*, *13*(1), 3453.
- Ort, A., Smallridge, J. W., Sarasso, S., Casarotto, S., von Rotz, R., Casanova, A., Seifritz, E., Preller, K. H., Tononi, G., & Vollenweider, F. X. (2023). Tms-eeg and resting-state eeg applied to altered states of consciousness: Oscillations, complexity, and phenomenology. *Iscience*, *26*(5).
- Overall, J. E., & Gorham, D. R. (1962). The brief psychiatric rating scale. *Psychological reports*, *10*(3), 799–812.
- Pallavicini, C., Vilas, M. G., Villarreal, M., Zamberlan, F., Muthukumaraswamy, S., Nutt, D., Carhart Harris, R., & Tagliazucchi, E. (2019). Spectral signatures of serotonergic psychedelics and gluta matergic dissociatives. *Neuroimage*, 200, 281–291.
- Preller, K. H., Razi, A., Zeidman, P., Stämpfli, P., Friston, K. J., & Vollenweider, F. X. (2019). Effective
 connectivity changes in lsd-induced altered states of consciousness in humans. *Proceedings of the National Academy of Sciences*, *116*(7), 2743–2748.
- Preller, K. H., & Vollenweider, F. X. (2018). Phenomenology, structure, and dynamic of psychedelic
 states. *Behavioral neurobiology of psychedelic drugs*, 221–256.
- Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M.
 (2021). A single dose of psilocybin increases synaptic density and decreases 5-ht2a receptor density
 in the pig brain. *International journal of molecular sciences*, 22(2), 835.
- Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016). Receptor interaction profiles of novel
 psychoactive tryptamines compared with classic hallucinogens. *European Neuropsychopharmacol- ogy*, 26(8), 1327–1337.
- Rolls, E. T., Huang, C.-C., Lin, C.-P., Feng, J., & Joliot, M. (2020). Automated anatomical labelling atlas 3. *Neuroimage*, *206*, 116189.
- Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of acute psychedelic experience predicts
 therapeutic efficacy of psilocybin for treatment-resistant depression. *Frontiers in pharmacology*,
 8, 309463.
- Rosenblat, J. D., Leon-Carlyle, M., Ali, S., Husain, M. I., & McIntyre, R. S. (2023). Antidepressant effects
 of psilocybin in the absence of psychedelic effects. *American Journal of Psychiatry*, 180(5), 395–396.
- Schartner, M., Seth, A., Noirhomme, Q., Boly, M., Bruno, M.-A., Laureys, S., & Barrett, A. (2015). Com plexity of multi-dimensional spontaneous eeg decreases during propofol induced general anaes thesia. *PloS one*, *10*(8), e0133532.
- Schartner, M. M., Carhart-Harris, R. L., Barrett, A. B., Seth, A. K., & Muthukumaraswamy, S. D.
 (2017). Increased spontaneous meg signal diversity for psychoactive doses of ketamine, lsd and
 psilocybin. *Scientific reports*, 7(1), 46421.

It is made available under a CC-BY-NC-ND 4.0 International license .

- Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker,
 R., Dunbar, G. C., et al. (1998). The mini-international neuropsychiatric interview (mini): The
 development and validation of a structured diagnostic psychiatric interview for dsm-iv and icd-10.
 Journal of clinical psychiatry, *59*(20), 22–33.
- Siegel, J. S., Subramanian, S., Perry, D., Kay, B., Gordon, E., Laumann, T., Reneau, R., Gratton, C.,
 Horan, C., Metcalf, N., et al. (2023). Psilocybin desynchronizes brain networks. *medRxiv*.
- Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012). Prediction of psilocybin response
 in healthy volunteers. *PloS one*, 7(2), e30800.
- Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011). Acute, subacute and long-term
 subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies.
 Journal of psychopharmacology, 25(11), 1434–1452.
- Timmermann, C., Roseman, L., Haridas, S., Rosas, F. E., Luan, L., Kettner, H., Martell, J., Erritzoe, D.,
 Tagliazucchi, E., Pallavicini, C., et al. (2023). Human brain effects of dmt assessed via eeg-fmri.
 Proceedings of the National Academy of Sciences, *120*(13), e2218949120.
- Timmermann, C., Roseman, L., Schartner, M., Milliere, R., Williams, L. T., Erritzoe, D., Muthukumaraswamy, S., Ashton, M., Bendrioua, A., Kaur, O., et al. (2019). Neural correlates of the dmt experience assessed with multivariate eeg. *Scientific reports*, *9*(1), 16324.
- Tyls, F., Palenicek, T., Viktorinova, M., Prokopcova, D., Korcak, J., Androvicova, R., Brunovsky, M., Horacek, J. (2016). Psilocybin clinical trial: Acute effects and its relationship to the brain activity as measured by quantitative eeg. *Int J Neuropsychopharmacol*, *19*, 233.
- Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B.,
 Joliot, M. (2002). Automated anatomical labeling of activations in spm using a macroscopic
 anatomical parcellation of the mni mri single-subject brain. *Neuroimage*, 15(1), 273–289.
- Viktorin, V., Griškova-Bulanova, I., Voicikas, A., Dojčánová, D., Zach, P., Bravermanová, A., Andrashko,
 V., Tylš, F., Korčák, J., Viktorinová, M., et al. (2022). Psilocybin—mediated attenuation of
 gamma band auditory steady-state responses (assr) is driven by the intensity of cognitive and
 emotional domains of psychedelic experience. *Journal of personalized medicine*, *12*(6), 1004.
- Wallach, J., Cao, A. B., Calkins, M. M., Heim, A. J., Lanham, J. K., Bonniwell, E. M., Hennessey, J. J.,
 Bock, H. A., Anderson, E. I., Sherwood, A. M., et al. (2023). Identification of 5-ht2a receptor
 signaling pathways responsible for psychedelic potential. *bioRxiv*.
- Wießner, I., Falchi, M., Palhano-Fontes, F., Oliveira Maia, L., Feilding, A., Ribeiro, S., Bezerra Mota,
 N., Araujo, D. B., & Tófoli, L. F. (2021). Low-dose lsd and the stream of thought: Increased
 discontinuity of mind, deep thoughts and abstract flow. *Psychopharmacology*, 1–13.
- Yu, C.-L., Liang, C.-S., Yang, F.-C., Tu, Y.-K., Hsu, C.-W., Carvalho, A. F., Stubbs, B., Thompson, T.,
 Tsai, C.-K., Yeh, T.-C., et al. (2022). Trajectory of antidepressant effects after single-or two-

It is made available under a CC-BY-NC-ND 4.0 International license .

40

REFERENCES

dose administration of psilocybin: A systematic review and multivariate meta-analysis. *Journal of clinical medicine*, *11*(4), 938.